Sign inJoin waitlistJoin the waitlist

Trisha Wise-Draper

Section Chief of Medical Oncology, Division of Hematology Oncology · University of Cincinnati Medical Center Inc.

Credentials: · · · · · ·

History

Division of Hematology Oncology Section · University of Cincinnati Medical Center Inc.
Present
University of Cincinnati Medical Center Inc.
Present
University of Cincinnati Medical Center Inc. · Indiana University School of Medicine
Present

Hematology and Medical Oncology
University of Cincinnati
2017–2020
University Hospitals Community Consortium
2014–2017
Internal Medicine
University of Cincinnati Medical Center Inc.
2011–2014
University of Cincinnati College of Medicine
2006–2010
Miami University (Zoology
2002–2006

Research

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Cancer Discovery · 2020 · 312 citations
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Annals of Oncology · 2021 · 260 citations
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research · 2022 · First of 26 authors · 178 citations

Vinita Takiar
29 papers
Alice Tang
15 papers · 1 as a fellow
Shuchi Gulati
13 papers · 3 as a fellow
Clara Hwang
12 papers
Jeremy Warner
12 papers
MP
Matthew Puc
12 papers
Rana McKay
12 papers · 2 as a resident
Chris Labaki
10 papers · 2 as a resident
Ben Hinrichs
8 papers
Chinmay Jani
8 papers
Keith Casper
8 papers
Stephanie Berg
8 papers

Grants

Optimization of Peripheral Blood Mononuclear Cell (PBMC) Processing for Robust Downstream Functional Immune Cell Analysis and Correlation with Therapeutic Efficacy
National Cancer Institute · U01
Contact PI · $1.8M · University of Cincinnati
2022–2027

Clinical trials

Amivantamab in Adenoid Cystic Carcinoma
Principal investigator · Active not recruiting · Phase 2
Trisha Wise-Draper
2022–2028
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Principal investigator · Completed · Phase 2
Trisha Wise-Draper
2020–2026
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
Principal investigator · Active not recruiting · Phase 2
Trisha Wise-Draper
2020–2026
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Principal investigator · Completed · Phase 2
University of Cincinnati
2018–2024